A recent study by Hussain et al. [21] showed that patients with PCa harboring at least one mutation in BRCA1, BRCA2 or ATM who received the PARP inhibitor olaparib had significantly longer survival than those who received enzalutamide or abiraterone plus prednisone as control therapy. Here, BRCA2 is linked to posterior cortical atrophy.